However, according to the ESE guidelines, gonadotropin, TT, and sexual hormone binding globulin (SHBG) for the determination of bioavailable testosterone must be assessed only in the presence of known signs/symptoms of hypogonadism [1]. This evidence concerns the gene SHBG and hypogonadism.